<DOC>
	<DOC>NCT02888236</DOC>
	<brief_summary>A study of LEO 32731 in the treatment of psoriasis vulgaris</brief_summary>
	<brief_title>LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris</brief_title>
	<detailed_description>This is an investigation of the efficacy of LEO 32731 30 mg as compared to placebo after 16 weeks of oral treatment of psoriasis vulgaris</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed and dated informed consent Aged between 18 years and 65. Males or females of nonchildbearing potential. Clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis Have moderate to severe psoriasis vulgaris Candidates of systemic antipsoriatic treatment and/or phototherapy Subjects with therapy resistant psoriasis Previously exposed to apremilast Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris Systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>